Allergy Therapeutics PLC Announces Board Change
(firmenpresse) - WORTHING, UNITED KINGDOM -- (Marketwired) -- 03/17/16 -- Allergy Therapeutics (AIM: AGY)
AIM: AGY
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Ian Postlethwaite, Finance Director, has resigned from the Company to pursue a new opportunity. Ian will remain as a Director of the Company and Finance Director for up to six months to allow time for a suitable successor to be appointed and for an orderly handover. The Board has commenced a search for his successor and a further announcement will be made in due course.
: "Ian has been the Finance Director for 14 years and a significant contributor to the success of the Company. During this time Allergy Therapeutics has listed on AIM, achieved a number of financial goals including two fund raisings in 2015 to support the Company''s clinical and other development plans, and has growing revenues from products on sale in Europe. Ian leaves the Company in the strongest position it has ever been in, in terms of sales, cash balance and growth potential. We are very positive about the future of Allergy Therapeutics and wish Ian the best for his ongoing career."
ENDS
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton
Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM: AGY). For more information please see .
This information is provided by RNS
The company news service from the London Stock Exchange
Contact:
RNS
Customer Services
0044-207797-4400
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.03.2016 - 02:00 Uhr
Sprache: Deutsch
News-ID 1422360
Anzahl Zeichen: 3524
contact information:
Contact person:
Town:
WORTHING, UNITED KINGDOM
Phone:
Kategorie:
Healthcare
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Allergy Therapeutics PLC Announces Board Change
"
steht unter der journalistisch-redaktionellen Verantwortung von
Allergy Therapeutics PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
